, Volume 18, Issue 4, pp 500–508 | Cite as

Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system

  • V. S. NunesEmail author
  • J. M. S. Correa
  • M. E. S. Puga
  • E. M. K. Silva
  • C. L. Boguszewski


Whether the preoperative use of somatostatin analogues (SA) improves surgical outcomes in acromegaly is still a matter of debate.


We conducted a systematic review of randomized, controlled trials that compared the short-term outcomes of preoperative use of SA (Pre-SA) with direct TSS (No-SA) for the treatment of newly diagnosed acromegaly.


Embase, Pubmed, Lilacs, and Central Cochrane were used as our data sources. The primary outcomes were no need for any adjuvant treatment 3 months after surgery, based on biochemical results (GH nadir after OGTT <1 μg/L and normal IGF-1 for age and gender), quality of life and mortality. The included trials were analyzed using the Grading of Recommendations Assessment, Development, and Evaluation approach.


A total of 2.099 references were identified and two reviewers independently screened the titles and abstracts. From the 14 potentially eligible studies, four were included and ten were excluded due to lack of randomization or different outcomes. A pool of 261 patients was randomly assigned to Pre-SA or No-SA. Meta-analysis of IGF1 normalization showed a significant difference in favor of Pre-SA (RR 2.47; 95 % CI 1.66, 3.77). Adding a GH nadir on OGTT ≤1 μg/L, we found a RR of 2.15 (95 % CI 1.39, 3.33). Quality of evidence for no need of adjuvant postoperative treatment was moderate, but for improving quality of life was very low and for mortality was absent.


Pre-SA increases the chance of biochemical control of acromegaly 3 months after TSS in patients harboring GH-secreting pituitary macroadenomas.


Acromegaly Somatostatin analogues Systematic review Meta-analysis 



We thank Dr. Gordon H. Guyatt to help us to apply the GRADE system in this Systematic Review and Dr. Sergio Alberto Rupp de Paiva to motivate us to use the GRADE approach. This work was supported by Sao Paulo State Research Foundation (FAPESP); Grant # 2011/20517-2.

Conflict of interest

V. S. Nunes and C. L. Boguszewski receive consulting fees from Novartis and travel expenses from Ipsen. J. M. S. Correa, M. E. S. Puga and E. M. K. Silva have no relationships to disclose.


  1. 1.
    Melmed S, Colao A, Barkan A et al (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509–1517. doi: 10.1210/jc.2008-2421 PubMedCrossRefGoogle Scholar
  2. 2.
    Melmed S (2006) Acromegaly. N Engl J Med 355:2558–2573. doi: 10.1111/j.1365-2036.2011.04905.x PubMedCrossRefGoogle Scholar
  3. 3.
    Vieira Neto L, Abucham J, de Araujo LA et al (2011) Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol 55:91–105. doi: 10.1590/S0004-27302011000200001 PubMedCrossRefGoogle Scholar
  4. 4.
    Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical “cure”. Eur J Endocrinol 152:379–387. doi: 10.1530/eje.1.01863 PubMedCrossRefGoogle Scholar
  5. 5.
    Wass JA, Turner HE, Adams CB, HE, Adams CB (1999) The importance of locating a good pituitary surgeon. Pituitary 2:51–54PubMedCrossRefGoogle Scholar
  6. 6.
    Stevenaert A, Harris AG, Kovacs K, Beckers A (1992) Presurgical octreotide treatment in acromegaly. Metabolism 51–58Google Scholar
  7. 7.
    Abe T, Lüdecke DK (2001) Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145:137–145. doi: 10.1530/eje.0.1450137 PubMedCrossRefGoogle Scholar
  8. 8.
    Colao A, Ferone D, Cappabianca P et al (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308–3314. doi: 10.1097/00019616-199803000-00020 PubMedCrossRefGoogle Scholar
  9. 9.
    Barkan AL, Lloyd RV, Chandler WF et al (1988) Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67:1040–1048PubMedCrossRefGoogle Scholar
  10. 10.
    Biermasz NR, van Dulken H, Roelfsema F (1999) Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 84:3551–3555PubMedCrossRefGoogle Scholar
  11. 11.
    Kristof RA, Stoffel-Wagner B, Klingmüller D, Schramm J (1999) Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir (Wien) 141:399–405. doi: 10.1007/s007010050316 CrossRefGoogle Scholar
  12. 12.
    The Cochrane Collaboration (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Version 510 [updated March 2011] Cochrane Collab.
  13. 13.
    Guyatt GH, Oxman AD, Kunz R et al (2008) What is “quality of evidence” and why is it important to clinicians? BMJ Br Med J 336:995–998. doi: 10.1136/bmj.39490.551019.BE CrossRefGoogle Scholar
  14. 14.
    Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383–394. doi: 10.1016/j.jclinepi.2010.04.026 PubMedCrossRefGoogle Scholar
  15. 15.
    Carlsen SM, Lund-Johansen M, Schreiner T et al (2008) Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93:2984–2990. doi: 10.1210/jc.2008-0315 PubMedCrossRefGoogle Scholar
  16. 16.
    Shen M, Shou X, Wang Y et al (2010) Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J 57:1035–1044. doi: 10.1507/endocrj.K10E-203 PubMedCrossRefGoogle Scholar
  17. 17.
    Mao Z, Zhu Y, Tang H et al (2010) Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol 162:661–666. doi: 10.1530/EJE-09-0908 PubMedCrossRefGoogle Scholar
  18. 18.
    Li Z-Q, Quan Z, Tian H-L, Cheng M (2012) Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. J Int Med Res 40:517–524. doi: 10.1177/147323001204000213 PubMedCrossRefGoogle Scholar
  19. 19.
    Carlsen SM, Svartberg J, Schreiner T et al (2011) Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clin Endocrinol (Oxf) 74:736–743. doi: 10.1111/j.1365-2265.2011.03982.x CrossRefGoogle Scholar
  20. 20.
    Losa M, Mortini P, Urbaz L et al (2006) Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 104:899–906. doi: 10.3171/jns.2006.104.6.899 PubMedCrossRefGoogle Scholar
  21. 21.
    Plöckinger U, Quabbe H-J (2005) Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir (Wien) 147:485–493; discussion 493. doi: 10.1007/s00701-005-0511-9
  22. 22.
    Waśko R, Ruchała M, Sawicka J et al (2000) Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly. J Endocrinol Invest 23:12–18PubMedCrossRefGoogle Scholar
  23. 23.
    Ezzat S, Kontogeorgos G, Redelmeier DA et al (1995) In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 133:686–690. doi: 10.1530/eje.0.1330686 PubMedCrossRefGoogle Scholar
  24. 24.
    Thapar K, Kovacs KT, Stefaneanu L et al (1997) Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial. Mayo Clin Proc 72:893–900. doi: 10.4065/72.10.893 PubMedGoogle Scholar
  25. 25.
    Cannavò S, Squadrito S, Curtò L et al (2001) Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Horm Metab Res 33:618–624. doi: 10.1055/s-2001-17910 PubMedCrossRefGoogle Scholar
  26. 26.
    Giustina A, Chanson P, Kleinberg D et al (2014) Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10:243–248. doi: 10.1038/nrendo.2014.21 PubMedCrossRefGoogle Scholar
  27. 27.
    Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S et al (2013) Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS One. doi: 10.1371/journal.pone.0061523 PubMedCentralPubMedGoogle Scholar
  28. 28.
    Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin Epidemiol 64:1294–1302. doi: 10.1016/j.jclinepi.2011.03.017 PubMedCrossRefGoogle Scholar
  29. 29.
    Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 8. Rating the quality of evidence—indirectness. J Clin Epidemiol 64:1303–1310. doi: 10.1016/j.jclinepi.2011.04.014 PubMedCrossRefGoogle Scholar
  30. 30.
    Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol 64:1283–1293. doi: 10.1016/j.jclinepi.2011.01.012 PubMedCrossRefGoogle Scholar
  31. 31.
    Guyatt GH, Oxman AD, Montori V et al (2011) GRADE guidelines: 5. Rating the quality of evidence—publication bias. J Clin Epidemiol 64:1277–1282. doi: 10.1016/j.jclinepi.2011.01.011 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • V. S. Nunes
    • 1
    Email author
  • J. M. S. Correa
    • 1
  • M. E. S. Puga
    • 2
  • E. M. K. Silva
    • 2
  • C. L. Boguszewski
    • 3
  1. 1.Department of Internal Medicine, Botucatu Medical SchoolSao Paulo State University/UNESPSao PauloBrazil
  2. 2.Brazilian Cochrane Centre - Discipline of Emergency Medicine and Evidence-Based MedicineFederal University of Sao Paulo (UNIFESP)São PauloBrazil
  3. 3.Department of Internal Medicine, Endocrine Division (SEMPR)Federal University of ParanaCuritibaBrazil

Personalised recommendations